Cardiac Amyloidosis Global Market Report 2025

Description

Cardiac amyloidosis is a condition characterized by the deposition of abnormal amyloid proteins in the heart tissue, resulting in stiffness and impaired function. This leads to heart failure, arrhythmias, and other cardiovascular complications. Early diagnosis and treatment are essential for managing symptoms and slowing disease progression.

The primary types of cardiac amyloidosis are light-chain amyloidosis and transthyretin amyloidosis. Light-chain amyloidosis (AL amyloidosis) is a disorder in which misfolded immunoglobulin light chains form amyloid deposits in various organs, including the heart, causing dysfunction and potential organ failure. Treatment options include chemotherapy, surgery, supportive care, stem cell transplantation, and targeted therapy. The disease is primarily managed in hospitals, ambulatory surgical centers, and clinics.

The cardiac amyloidosis market research report is one of a series of new reports from The Business Research Company that provides cardiac amyloidosis market statistics, including the cardiac amyloidosis industry global market size, regional shares, competitors with the cardiac amyloidosis market share, detailed cardiac amyloidosis market segments, market trends, and opportunities, and any further data you may need to thrive in the cardiac amyloidosis industry. This cardiac amyloidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cardiac amyloidosis market size has grown strongly in recent years. It will grow from $5.26 billion in 2024 to $5.75 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth during the historic period can be attributed to the increasing prevalence of amyloidosis-related conditions, genetic mutations, heightened awareness, a rising number of transthyretin amyloidosis cases, and the growing geriatric population.

The cardiac amyloidosis market size is expected to see strong growth in the next few years. It will grow to $8.10 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth during the forecast period can be attributed to higher diagnosis rates, government support and initiatives, the rising prevalence of genetic mutations, and patient assistance programs. Key trends expected in this period include the development of new therapies such as vutrisiran, expanding research in gene therapy, a focus on precision medicine, advancements in diagnostic technologies, and the emergence of novel treatments.

The rising geriatric population is expected to drive the growth of the cardiac amyloidosis market in the coming years. The geriatric population refers to individuals aged 65 and older who often require specialized healthcare due to age-related conditions. The steady increase in this population is driven by rising life expectancy, advancements in medical care, and declining birth rates. Since aging is a significant risk factor for amyloid protein accumulation in the heart, the growing number of older adults contributes to the increasing prevalence of cardiac amyloidosis. For example, according to the Population Reference Bureau, a US-based nonprofit organization, the US population aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. As a result, the expanding geriatric demographic is expected to fuel the growth of the cardiac amyloidosis market.

Leading companies in the cardiac amyloidosis market are focusing on technological advancements, such as artificial intelligence (AI)-based diagnostic tools, to improve early disease detection and enhance clinical outcomes. AI-powered, software-only medical devices can analyze echocardiographic images and identify signs of cardiac amyloidosis without the need for additional hardware or extensive clinical data. For instance, in November 2024, Ultromics Ltd., a UK-based health technology company, secured FDA clearance for EchoGo Amyloidosis, an AI-driven clinical tool for early cardiac amyloidosis detection. It is the first device in the FDA's Total Product Lifecycle Advisory Program (TAP) to receive marketing authorization. Using AI, EchoGo Amyloidosis analyzes echocardiograms from a single clip, enabling earlier detection before the disease progresses undetected.

In January 2024, Ultromics Ltd. partnered with Pfizer Inc. to further develop its Echo AI algorithm for cardiac amyloidosis detection. This partnership aims to enhance diagnostic accuracy and improve patient outcomes. Pfizer Inc. is a US-based pharmaceutical company specializing in innovative medicines, including treatments for cardiac amyloidosis, as well as consumer healthcare products.

Major players in the cardiac amyloidosis market are Pfizer Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Alexion Pharmaceuticals Inc., Dr. Reddy's Laboratories, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., BridgeBio Pharma Inc., Prothena Corp, Intellia Therapeutics Inc., Amylyx Pharmaceuticals, Neurimmune AG, SOM Biotech, Oncopeptides, Attralus Inc., and Eidos Therapeutics.

North America was the largest region in the cardiac amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cardiac amyloidosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cardiac amyloidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cardiac amyloidosis market consists of revenues earned by entities by providing services such as early diagnosis through imaging and biomarker testing, medication management, and supportive therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac amyloidosis market also includes sales of diagnostic imaging tools, biomarker testing kits, and disease-modifying therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cardiac Amyloidosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cardiac amyloidosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cardiac amyloidosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cardiac amyloidosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product Type: Light Chain Amyloidosis; Transthyretin Amyloidosis
2) By Treatment: Chemotherapy; Surgery; Supportive Care; Stem Cell Transplant; Targeted Therapy
3) By End-User: Hospitals; Ambulatory Surgical Centres; Clinics
Subsegments:
1) By Light Chain Amyloidosis: Immunoglobulin Light Chain (AL) Amyloidosis; Primary Light Chain Amyloidosis; Secondary Light Chain Amyloidosis
2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm); Wild-type Transthyretin Amyloidosis (ATTRwt)
Companies Mentioned: Pfizer Inc.; Sanofi S.A.; AstraZeneca plc; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r33994

1. Executive Summary

2. Cardiac Amyloidosis Market Characteristics

3. Cardiac Amyloidosis Market Trends And Strategies

4. Cardiac Amyloidosis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Cardiac Amyloidosis Growth Analysis And Strategic Analysis Framework

5.1. Global Cardiac Amyloidosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Cardiac Amyloidosis Market Growth Rate Analysis
5.4. Global Cardiac Amyloidosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Cardiac Amyloidosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Cardiac Amyloidosis Total Addressable Market (TAM)

6. Cardiac Amyloidosis Market Segmentation

6.1. Global Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Light Chain Amyloidosis
Transthyretin Amyloidosis
6.2. Global Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Surgery
Supportive Care
Stem Cell Transplant
Targeted Therapy
6.3. Global Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Ambulatory Surgical Centres
Clinics
6.4. Global Cardiac Amyloidosis Market, Sub-Segmentation Of Light Chain Amyloidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunoglobulin Light Chain (AL) Amyloidosis
Primary Light Chain Amyloidosis
Secondary Light Chain Amyloidosis
6.5. Global Cardiac Amyloidosis Market, Sub-Segmentation Of Transthyretin Amyloidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hereditary Transthyretin Amyloidosis (ATTRm)
Wild-type Transthyretin Amyloidosis (ATTRwt)

7. Cardiac Amyloidosis Market Regional And Country Analysis

7.1. Global Cardiac Amyloidosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Cardiac Amyloidosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cardiac Amyloidosis Market

8.1. Asia-Pacific Cardiac Amyloidosis Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cardiac Amyloidosis Market

9.1. China Cardiac Amyloidosis Market Overview
9.2. China Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cardiac Amyloidosis Market

10.1. India Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cardiac Amyloidosis Market

11.1. Japan Cardiac Amyloidosis Market Overview
11.2. Japan Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cardiac Amyloidosis Market

12.1. Australia Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cardiac Amyloidosis Market

13.1. Indonesia Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cardiac Amyloidosis Market

14.1. South Korea Cardiac Amyloidosis Market Overview
14.2. South Korea Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cardiac Amyloidosis Market

15.1. Western Europe Cardiac Amyloidosis Market Overview
15.2. Western Europe Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cardiac Amyloidosis Market

16.1. UK Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cardiac Amyloidosis Market

17.1. Germany Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cardiac Amyloidosis Market

18.1. France Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cardiac Amyloidosis Market

19.1. Italy Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cardiac Amyloidosis Market

20.1. Spain Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cardiac Amyloidosis Market

21.1. Eastern Europe Cardiac Amyloidosis Market Overview
21.2. Eastern Europe Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cardiac Amyloidosis Market

22.1. Russia Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cardiac Amyloidosis Market

23.1. North America Cardiac Amyloidosis Market Overview
23.2. North America Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cardiac Amyloidosis Market

24.1. USA Cardiac Amyloidosis Market Overview
24.2. USA Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cardiac Amyloidosis Market

25.1. Canada Cardiac Amyloidosis Market Overview
25.2. Canada Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cardiac Amyloidosis Market

26.1. South America Cardiac Amyloidosis Market Overview
26.2. South America Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cardiac Amyloidosis Market

27.1. Brazil Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cardiac Amyloidosis Market

28.1. Middle East Cardiac Amyloidosis Market Overview
28.2. Middle East Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cardiac Amyloidosis Market

29.1. Africa Cardiac Amyloidosis Market Overview
29.2. Africa Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cardiac Amyloidosis Market Competitive Landscape And Company Profiles

30.1. Cardiac Amyloidosis Market Competitive Landscape
30.2. Cardiac Amyloidosis Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Cardiac Amyloidosis Market Other Major And Innovative Companies

31.1. Novo Nordisk A/S
31.2. Alexion Pharmaceuticals Inc.
31.3. Dr. Reddy's Laboratories
31.4. Alnylam Pharmaceuticals Inc.
31.5. Ionis Pharmaceuticals Inc.
31.6. Akcea Therapeutics Inc.
31.7. BridgeBio Pharma Inc.
31.8. Prothena Corp
31.9. Intellia Therapeutics Inc.
31.10. Amylyx Pharmaceuticals
31.11. Neurimmune AG
31.12. SOM Biotech
31.13. Oncopeptides
31.14. Attralus Inc.
31.15. Eidos Therapeutics

32. Global Cardiac Amyloidosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cardiac Amyloidosis Market

34. Recent Developments In The Cardiac Amyloidosis Market

35. Cardiac Amyloidosis Market High Potential Countries, Segments and Strategies

35.1 Cardiac Amyloidosis Market In 2029 - Countries Offering Most New Opportunities
35.2 Cardiac Amyloidosis Market In 2029 - Segments Offering Most New Opportunities
35.3 Cardiac Amyloidosis Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer